David Hering is CEO at Adagio Therapeutics, Inc. (ADGI). They have made 1 open-market trade across 1 company since 2022, most recently 2022-09-01.
CIK 0001875613
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $36K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADGI | 8,000 | $37K |
Shares reported on the most recent Form 4, priced at the 2022-09-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADGI | BUY | 2022-09-01 | 2022-09-01 | $4.52 | $36K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.